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Abstract
Tumor lysis syndrome (TLS) is widely recognized as a serious adverse event associated with the cytotoxic therapies
primarily used in hematologic cancers, such as Burkitt lymphoma and acute lymphoblastic leukemia. In recent years,
TLS has been more widely observed, due at least in part to the availability of more effective cancer treatments.
Moreover, TLS is seen with greater frequency in solid tumors, and particularly in bulky tumors with extensive
metastases and tumors with organ or bone marrow involvement. The consequences of TLS include the serious
morbidity and high risk of mortality associated with the condition itself. Additionally, TLS may delay or force an
alteration in the patient’s chemotherapy regimen. The changing patterns of TLS, as well as its frequency, in the
clinical setting, result in unnecessarily high rates of illness and/or fatality. Prophylactic measures are widely available
for patients at risk of TLS, and are considered highly effective. The present article discusses the various
manifestations of TLS, its risk factors and management options to prevent TLS from occurring.
Keywords: Acute renal failure, Allopurinol, Adverse events, Hematologic malignancies, Management, Prophylactic
therapy, Solid tumors, Tumor lysis syndrome (TLS), Rasburicase, Uric acid
Introduction
In recent years, tumor lysis syndrome (TLS), an oncolo-
gic emergency typically associated with cytotoxic therap-
ies, is more likely to be seen across a spectrum of cancer
types [1-3]. Previously regarded as a risk primarily in
hematologic malignancies such as Burkitt lymphoma
and acute lymphoblastic leukemia (ALL), TLS is now
observed in malignancies that had rarely been associated
with TLS, including solid tumors [4-9]. This change in
pattern is likely the result of several factors including the
availability of effective cytotoxic therapies for a wider
range of malignancies, as well as an insufficient use of
prophylactic therapies to adequately prevent TLS [1].
Although healthcare providers have expressed concerns
regarding the TLS risk related to newer chemo modal-
ities, they are not consistently utilizing straightforward
measures for reducing TLS risk in their extended
spectrum of patients at risk for TLS [2,10,11]. With
increasingly powerful chemotherapy agents being used
to treat patients, it is more important than ever that
patients undergo risk assessment for TLS in order that
they may receive appropriate treatment to reduce the
risk of occurrence. In the present article, we explore sev-
eral key areas relevant to the evolving knowledge of TLS
prevention that reflect the changing nature of the dis-
ease in the current clinical setting, and some frequently
overlooked issues important to an understanding of
TLS. In addition, we review the current and changing
approaches to risk assessment and management of TLS.
Definition of TLS
TLS occurs when the cellular components of tumor cells
are released into the blood after lysis, typically after
chemotherapy or radiation therapy [10]. It is character-
ized by hyperuricemia, hyperkalemia, hyperphosphate-
mia, and hypocalcemia, factors which may overtax the
body’s homeostatic mechanisms and overwhelm the
capacity for normal excretion of these materials [10,12].
This, in turn, causes various manifestations of TLS,
including acute renal failure [10,12] and cardiac arrest
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due to electrolyte abnormalities [10]. Malignancies,
which typically result in TLS, are ones that possess a
high proliferation rate and/or a large tumor burden,
such as lymphomas and acute leukemias [10,13]. More-
over, patients whose melanoma is particularly sensitive
to chemotherapy are also more likely to experience TLS
[13]. Spontaneous TLS – that is, TLS occurring in the
absence of cytotoxic therapy – is another concern
among patients with malignancies who are at risk for
TLS, and many of the same risk factors and preventive
measures appropriate for TLS also apply to spontaneous
TLS [6].
The standard definition for TLS comprises two separ-
ate definitions— clinical TLS (CTLS) and laboratory
TLS (LTLS) — standardized by Cairo & Bishop in 2004,
and based on an earlier definition by Hande & Garrow
in 1993 [14,15] (Table 1). In 2011, Howard et al. sug-
gested revisions to the Cairo & Bishop definitions [1].
The modified Howard definition of LTLS is ≥2 of the
following metabolic abnormalities occurring simultan-
eously within 3 days prior to and up to 7 days after
treatment initiation: hyperuricemia (>8.0 mg/dl), hyper-
kalemia (>6.0 mmol/liter), hyperphosphatemia (>4.5 mg/
dl), and hypocalcemia (corrected Ca <7.0 mg/dl, ionized
Ca <1.12 mg/dl). The modified Howard definition for
CTLS is the same as laboratory-defined TLS, and is ac-
companied by elevated creatinine level, seizures, cardiac
dysrhythmia, or death. In addition, any symptomatic
hypocalcemia is considered diagnostic [1].
TLS in solid tumors
Although TLS has long been assumed to manifest pri-
marily in hematologic malignancies, case reports of TLS
in solid tumors have become increasingly common over
the last decade [4-9]. The diversity of these reports is
too broad to report comprehensively; however, below are
several examples of the occurrence of TLS in varying
types of solid tumors.
A 2006 publication by Mott et al. reported LTLS in
three different patients—two with breast cancer and one
with small cell carcinoma [16]. A 47-year old woman
with metastatic breast cancer previously treated with
doxorubicin and docetaxel developed TLS with diagnosis
based on increased uric acid (UA) and lactate dehydro-
genase (LDH), after initiating treatment with fluorouracil
(5FU), epirubicin and cyclophosphamide (FEC). Her
Table 1 Comparison of tumor lysis syndrome (TLS) definitions




≥2 of the following metabolic abnormalities occurring within
4 days of treatment:
Laboratory-defined TLS accompanied
by any of the following:
_
○ 25% increase from baseline in UA ○ Creatinine level >221 μmol/l (2.5 mg/dL)
○ 25% increase from baseline in potassium ○ Potassium level >6 mmol/L (6 mEq/L)
○ 25% increase from baseline in phosphate ○ Calcium <1.5 mmol/L (6 mg/dL)





≥2 of the following metabolic abnormalities occurring
simultaneously within 3 days prior to and up to 7 days
post-treatment initiation:
Laboratory-defined TLS accompanied by
any of the following:
_
○ UA ≥476 μmol/L or 25% increase from baseline ○ Elevated creatinine level (≥1.5 ULN for
patients >12 years of age or age-adjusted)
○ Potassium ≥6.0 mmol/L or 25% increase from baseline ○ Seizures
○ Phosphorous ≥2.1 mmol/L (children) ≥1.45 mmol/L (adults)
or 25% increase from baseline
○ Cardiac dysrhythmia




≥2 of the following metabolic abnormalities occurring
simultaneously within 3 days prior to and up to
7 post-treatment initiation:
Laboratory-defined TLS accompanied by








○ Potassium >6.0 mmol/L ○ Seizures
○ Phosphorus >4.5 mg/dL (1.5 mmol/L) or >6.5 mg/dL
(2.1 mmol/L) in children
○ Cardiac dysrhythmia
○ Death
○ Corrected* calcium <7.0 mg/dL (1.75 mmol/L) or
ionized calcium <1.12 mg/dL (0.3 mmol/L)
UA, uric acid; ULN, upper limit of normal.
*Corrected calcium in mg/dL = measured calcium level in mg/dL + 0.8 × (4 – albumin in g/dL).
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LDH and UA—though unrecorded prior to chemother-
apy—reached 916 IU/dL (normal range 60–200) and 10
mg/dL (normal range 2.4-7.9), respectively, after one day
of treatment. These levels decreased to some extent by
the evening of day 2, and although the UA level normal-
ized, LDH remained well above the normal range [16].
In the second case, a 44-year old woman with breast
cancer initially treated with docetaxel without complica-
tion developed TLS, after gemcitabine plus cisplatin was
initiated for metastatic disease. The patient’s laboratory
values were significant for elevated LDH, phosphorus,
potassium, UA, creatinine, and decreased calcium after 4
days of carboplatin and etoposide. Also reported was a
76-year-old woman with small cell carcinoma who
developed elevated UA, serum potassium, phosphorus,
and decreased calcium after 4 days of carboplatin and
etoposide [16].
TLS in non-small cell lung cancer (NSCLC) — both
squamous cell carcinoma and adenocarcinoma — has
been reported in several instances, including after treat-
ment with docetaxel, zoledronic acid, radiotherapy, and
in at least one case, arising spontaneously [6-9]. A pa-
tient with metastatic colon cancer, for whom chemother-
apy had been ruled out due to liver metastases causing
hyperbilirubinemia and transaminitis, underwent treat-
ment with the monoclonal antibody cetuximab [17].
Renal function deteriorated after 18 hours, and the pa-
tient experienced elevations in UA, phosphorus, potas-
sium, and decreased calcium, consistent with CTLS.
Intense tumor lysis (though not diagnostic for TLS)
was seen in a 33-year-old patient with hepatocellular
carcinoma who was treated with sorafenib, a tyrosine
kinase inhibitor [4]. Four days after treatment initiation,
he experienced fatigue and fever; laboratory studies
found that compared with pre-treatment baseline, his
potassium had increased and calcium decreased, al-
though creatinine and phosphorus were roughly un-
changed and his UA had decreased [4].
A 44-year-old patient with primary retroperitoneal
soft-tissue sarcoma was given a combination chemother-
apy regimen of cisplatin, adriamycin, and dacarbazine
after a chemosensitivity assay revealed that the malig-
nancy was sensitive to these agents [5]. After 4 days, the
patient experienced palpitations, dyspnea, chest tight-
ness, and oliguria, accompanied by abnormally high
creatinine as well as hyperuricemia, hyperphosphatemia,
hypocalcemia diagnostic for CTLS, and acute renal
failure. CTLS was also reported in a 60-year-old patient
with recurrent endometrial cancer who had been receiv-
ing carboplatin and paclitaxel [18]. Four days after re-
ceiving treatment with both agents, she presented to the
emergency room with dyspnea, weakness, fatigue, meta-
bolic and electrolyte abnormalities, as well as UA, potas-
sium, and phosphate levels consistent with TLS [18].
Case reports of TLS resulting from the treatment of
metastatic melanoma (MM) have also been published. A
56-year-old patient with abdominal pain, vomiting, and
weight loss, ongoing for 2 months, was diagnosed with
MM and treated with intravenous hydrocortisone for
hypercalcemia [19]. By the following day, lab values indi-
cated the onset of CTLS; treatment for TLS along with
discontinuation of the hydrocortisone resulted in a reso-
lution of symptoms [19]. A 61-year-old patient presented
with a nevus in the abdominal wall, and melanoma
extending to lateral margin and invading the lymphatic
channels was diagnosed and excision performed [20]. Six
months later, melanoma was found in 6 of 15 lymph
nodes, the MM having expanded despite treatment with
one cycle of granulocyte macrophage–colony stimulating
factor. Chemotherapy of cisplatin, vinblastine, and dacar-
bazine was initiated, along with interleukin-2 and inter-
feron-α. LDH rose dramatically within 24 hours. By day
3, CTLS symptoms had emerged and the following day
chemotherapy was discontinued.
A 41-year-old patient with metastatic melanoma
initiated on cisplatin, dacarbazine and interferon devel-
oped oliguria on day 2 after chemotherapy and symp-
toms of CTLS by day 4; acute renal failure developed
shortly thereafter [21]. The potential greater potency of
new chemotherapeutic regimens may be associated with
a heightened risk for TLS.
Spontaneous TLS
The term “spontaneous TLS” refers to manifestations of
TLS in patients who have not received cytotoxic therapy
[6]. As with treatment-related TLS, spontaneous TLS
was thought to be primarily confined to hematologic
cancers [6]. While this is largely the case, incidences of
spontaneous TLS in solid tumors have been reported
[11,13]. Case reports of spontaneous TLS in hematologic
cancers include cases occurring in patients with Burkitt
lymphoma, non-Hodgkin’s lymphoma, acute myeloid
leukemia, B-cell lymphoma, and ALL, among others
[11,22-27]. Solid tumors in which spontaneous TLS has
been observed include breast cancer, gastric cancer,
germ cell tumors, gastrointestinal adenocarcinoma,
squamous cell lung carcinoma, and metastatic castrate-
resistant prostate cancer [6,28-32]. Hyperphosphatemia
is less common in spontaneous than nonspontaneous
TLS, possibly because phosphate release in lysis is less
achievable when cytotoxic therapy has taken place [33].
TLS risk factors
Risk assessment is fundamental to the management of
TLS, particularly in light of the highly effective preven-
tion and treatment options available to clinicians. While
general risk factors for TLS are typically well under-
stood, stratifying patients with specific malignancy types,
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at specific disease stages, with particular disease mani-
festations is a considerably more complex task [13].
Cairo et al. developed several risk assessment models
that allow for risk estimation based on cancer type as
well as several key factors, including choice of chemo-
therapy, state of renal function, and disease stage, among
other considerations [34]. These models, while informative,
may be challenging to implement in the clinical setting, in
part because they comprise 6 separate algorithms. Howard
et al. developed a single simplified algorithm for risk assess-
ment together with recommended therapy which, while less
detailed, is somewhat more accessible for clinical purposes
[1] (Figure 1). An adaptation of an algorithm developed by
Wetzstein, for an overall approach to the management of
TLS, is seen in Figure 2.
Risk factors for TLS related to tumor size and expan-
sion include bulky tumor, wide metastatic dispersal, and
organ and/or bone marrow involvement [1,13]. TLS risk
is increased when a high potential for cell lysis exists; for
example, in cases of high proliferation and tumor sensi-
tivity to particular cytotoxic therapies, and during times
when therapy intensity is particularly high [35]. Patients’
health status, beyond malignancy-related factors, can
also influence the risk of TLS, including presence of
hypotension, dehydration, acidic urine (because of the
greater propensity of UA to crystalize at low pH), oli-
guria, pre-cancer nephropathy, and previous experience
with nephrotoxic agents [1,36]. Medications and other
compounds that tend to increase UA levels (Table 2) are
additional risk factors for TLS.
Considerations in the management of TLS
Several key considerations and specific tasks are funda-
mental in the management of TLS. These include risk
assessment, fluid management for TLS prophylaxis, and
appropriate drug therapy for prophylaxis and TLS treat-
ment. In addition, where rasburicase therapy will be ap-
plied, ongoing debates and current knowledge regarding
appropriate dosage amounts and approaches to dosing
(eg, flat dosing versus weight-based dosing) must be
taken into consideration.
Clinical experience suggests that provision of appro-
priate prophylactic therapy for TLS may be the differ-
ence between successful and unsuccessful outcomes in
at-risk patients [1]. Appropriate management of TLS
should be centered around risk assessment of cancer
patients, preventive treatment where appropriate, elec-
trolyte monitoring in patients undergoing cytotoxic ther-
apy, and rapid appropriate therapeutic intervention as
necessary [10].
Fluid management is key in the prevention of TLS [13].
This involves both the vigorous application of hydration
and diuresis to maintain a flow of urine that will dispose
of systemic UA and phosphate. Urine alkalinization with
sodium bicarbonate had been a standard approach in TLS
management to increase urate excretion [14]. Alkaliniza-
tion is, however, associated with a reduction in the solubil-
ity of calcium phosphate, thus potentially creating the
problem in the setting of hyperphosphatemia, a more ser-
ious condition than the one it aims to treat [1,13]. The
2008 guidelines for the management of TLS state that
sodium bicarbonate is no longer recommended for TLS
management [13]. The rationale for this recommendation
is that although alkalinization promotes UA excretion, it
has a relatively small impact on xanthine and hypoxan-
thine solubility. Allopurinol, a cornerstone of TLS preven-
tion, is used to prevent formation of UA. It decreases the
formation of UA by inhibition the enzyme (XO) that con-
verts xanthine to hypoxanthine to UA. Inhibition of XO
leads to increased levels of xanthine and hypoxanthine.
Therefore, due to the risk of both xanthine crystallization,
calcium phosphate precipitation, as well as the occurrence
of metabolic alkalosis associated with alkalization, the util-
ity of routine use of sodium bicarbonate for the preven-
tion of TLS has fallen out of favor [13]. Taken together,
this risk plus the risk of calcium phosphate precipitation,
as well as that of the metabolic alkalosis associated with
alkalinization, challenges the clinical utility of sodium bi-
carbonate. It is also the case that in patients being treated
with rasburicase, alkalinization has been associated with
the potential risk of acute renal failure, and the 2008 TLS
guidelines regard alkalinization as contraindicated in
patients treated with rasburicase [13,39].
Allopurinol is commonly used in TLS management to
reduce the conversion of xanthine and hypoxanthine to
UA, a process for which it is highly effective [13]. Allo-
purinol is, however, ineffective at reducing UA formed
prior to treatment, and its slow time to efficacy can ne-
cessitate delaying chemotherapy or reducing the dose of
chemotherapy for patients in acute renal failure. Due to
its low levels of solubility, allopurinol, by increasing sys-
temic levels of xanthine and hypoxanthine, can also pro-
mote obstructive uropathy [40]. Reduced clearance of
purine-based chemotherapeutic drugs is an additional
feature of allopurinol that may require the dose reduc-
tion of these chemotherapeutic agents [1,13].
Rasburicase, the first recombinant uricolytic agent, rap-
idly reduces UA levels by eliminating existing UA [1,41].
The efficacy of rasburicase in depleting UA involves its
enzymatic degradation of UA into allantoin, which is
highly soluble and is not associated with adverse effects
in human patients [1]. Investigators have demonstrated
rasburicase to be safe and effective for prophylaxis or
treatment of hyperuricemia in patients with leukemia or
lymphoma [41,42]. Rasburicase is FDA approved for ini-
tial management of pediatric and adult patients with
leukemia, lymphoma, and solid tumor malignancies who
are receiving anticancer therapy expected to result in
McBride and Westervelt Journal of Hematology & Oncology 2012, 5:75 Page 4 of 11
http://www.jhoonline.org/content/5/1/75
tumor lysis and subsequent elevation of plasma UA [43].
Rasburicase is recommended as a first-line therapy for
patients at high risk of TLS, and is also used in Europe to
treat intermediate-risk adult patients [13].
It should be noted that rasburicase is contraindicated
in patients with a glucose-6-phosphate dehydrogenase
(G6PD) deficiency as these patients are at an elevated
risk for hemolysis [43]. Patients who are more likely to
have a G6PD deficiency include African Americans and
some people of Mediterranean and Southeast Asian
descent [13].
The potential benefits of using rasburicase in sequen-
tial combination with allopurinol was explored in an
open-label phase III study in which 275 patients with
Figure 1 Tumor lysis syndrome treatment (TLS) stratification algorithm [1].
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hematologic malignancies were randomized to receive
allopurinol (300 mg/d) or rasburicase (0.20 mg/kg/d) or
both over a period of 5 days [2]. The sequential combin-
ation group received rasburicase on days 1 through 3
and allopurinol on days 3 through 5 with an overlap on
day 3. The response rates with regard to serum UA were
87% for those treated only with rasburicase, 78% for
those treated with the combination, and 66% for allopur-
inol monotherapy [2]. Rasburicase was significantly
more effective than allopurinol (P=0.001), while the
combination did not reach statistically significant super-
iority over allopurinol alone (P=0.06). Similar results
were observed in subgroups of patients at elevated risk
for TLS and for those with hyperuricemia at baseline.
Treatment-related AEs were rare and similar between
treatment groups. Two subjects in each of the mono-
therapy groups experienced acute renal failure (2% for
each group), while 5 subjects (5%) in the combination
therapy group experienced acute renal failure [2].
Dosing of rasburicase
The ideal method of dosing rasburicase has been an area
of some debate, with one-time dosing, either as a fixed or
weight-based dose, being preferred by many over weight-
based, multi-dose therapy. Indeed, despite the FDA’s dos-
ing recommendation of 0.2 mg/kg/d for up to 5 days,
most rasburicase prophylactic treatment in the United
States employs a flat dose of 3 mg to 7.5 mg daily [43]. A
series of small studies have demonstrated the efficacy of
a single fixed or weight-based dose of rasburicase in
reducing UA in TLS patients or patients at high risk for
TLS. Fixed-doses employed in these studies were 3 mg, 6
mg, and 7.5 mg. Weight-based dosing was either 0.15 or
 
Pretreatment of patients with tumor lysis
• Baseline labs:  CMP, UA, phosphorus, LDH
• Identify individual patient risk factors
High risk Intermediate risk Low risk
• Monitor for  TLS and complications
• Daily labs to include  CMP, phosphorus, 
calcium, LDH, and UA every 6-8 h
• Hydration: 2-3 L/m2/d  (unless renal 
insufficiency or oliguria present )
• Single-dose rasburicase 0.1-0.2 mg/kg 
IV ; more if needed (except in patients 
with G6PD)
• Monitor for TLS and complications
• Hydration: 2-3 L/m2/d
• Allopurinol prophylaxis (100-300 
mg, PO, q8h, daily). If 
hyperuricemia develops, treat 
with rasburicase
• Monitor for TL S and complications
• Normal hydration
• No prophylaxis for hyperuricemia 
except where signs of metabolic 
change, bulky and/or advanced 
disease and/or high proliferative 
disease  occur(in these cases, 
allopurinol should be considered)
Acute TLS
Transfer to special care unit; treat specific 
metabolic complications; monitor as warranted
Hyperuricemia Hyperkalemia Hyperphosphatemia Hypocalcemia
• Aggressive hydration for 
intermediate and high risk except in 
renal failure or oliguria
• Urine output monitored closely
• Allopurinol in intermediate risk
• In high or intermediate risk, 
rasburicase if allopurinol fails or if  
allergic to allopurinol 
• Diuretics may be used where no 
obstructive uropathy or 
hypovolemia are  present
• Alkalinization is not warranted 
except in patients with signs of 
metabolic acidosis
• Intervention required in >7 mEq/L 
(or where EKG shows widening of 
QRS)
Asymptomatic: 
• Sodium polystyrene sulfonate
Symptomatic: 
• For treatment of life-threatening 
arrhythmias, calcium gluconate via  
slow infusion can be given
• Regular insulin with glucose 
• Albuterol by nebulizer
• Eliminate phosphate from IV 
solutions, adequate hydration, 
phosphate binders may be utilized
• Sevelamer carbonate or calcium 
acetate (Titrate as needed)
• Calcium carbonate 
contraindicated where high 
calcium levels present 
• Hemodialysis, peritoneal dialysis, 
or continuous venovenous 
hemofiltration
• Calcium gluconate,  
administered slowly with EKG 
monitoring
• Careful consideration should 
be warranted in cases of high 
phosphate levels 
Figure 2 Algorithm for the management of tumor lysis syndrome (TLS) [3,13,34]. CMP, complete metabolic panel, EKG, electrocardiogram;
G6PD, glucose-6-phosphate dehydrogenase; IV, intravenous; LDH, lactic dehydrogenase; PO, by mouth.
Table 2 Compounds associated with increasing uric acid
in the body [37,38]
Alcohol Diazoxide Methyldopa
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Table 3 Pharmacologic therapies for the treatment of tumor lysis syndrome (TLS) [3]
Medication Mechanism of Action Dosage/Administration Comments
Hyperuricemia Allopurinol Potent inhibitor of xanthine
oxidase, the enzyme responsible
for the conversion of
hypoxanthine to xanthine to
uric acid.
PO: 200–300 mg/m2 qd;
administration of >300 mg
should be given in divided
doses (max, 800 mg/d); should




nausea/ vomiting, fever, and
eosinophilia; rare reports of
interstitial nephritis; decreases
in serum uric acid occur in 1
to 2 days with a nadir ~7 days;
dosage adjustment in renal
dysfunction is necessary to avoid
accumulation of the active
metabolite oxypurinol
(alloxanthine); removed by
dialysis, so administer post-




6-mercaptopurine; the dose of
concomitant azathioprine or
6-mercaptopurine should be
reduced to one third to one
fourth of their usual dose.
Adult (IV): 200–400 mg/m2/d as
a single infusion or divided doses
(max, 600 mg/d); infuse over 15–
60 minutes; final concentration no
greater than 6 mg/mL.
Pediatric (IV): Starting dose
200 mg/m2/d.
Rasburicase Recombinant protein that
catalyzes enzymatic oxidation
of uric acid into an inactive
metabolite, allantoin, that is 5
to 10 times more soluble
than uric acid.
Adult: 0.2 mg/kg infusion over
30 minutes once daily for up to
5 days*; no dosing adjustment
required in renal or hepatic
dysfunction.
Adverse events include nausea/
vomiting, fever, headache,
abdominal pain, constipation,
diarrhea, and rash. Rare (<1%)
but serious reactions have





is advised in patients who
have atopic allergies/asthma.
Pediatric: 0.15-0.2 mg/kg IV
infusion over 30 minutes daily ×
5 days*; no dosing adjustment
required in renal or hepatic
dysfunction.
*Studies using single dose in the





(G6PD). Rasburicase will cause
enzymatic degradation of uric
acid within blood samples left at
room temperature, resulting in
spuriously low uric acid levels—




maintained in an ice water bath;
plasma samples must be assayed





Removes potassium (K+) by
exchanging sodium ions (Na+)
for K+ in the intestine.
Adult: 15 g PO (60 mL) 1 to
4 times per day
1 g resin binds approximately
1 mEq of K+; onset is variable
~2 to 24 hours; administer orally
or nasogastrically with a
laxative such as sorbitol to
avoid fecal impaction and
facilitate elimination; chilling
the solution will increase
palatability; enema route is
usually less effective.




Raises threshold potential and
reestablishes cardiac excitability.
Adult: 1–3 g over 3 to 5 minutes
IV push.
Antagonizes the action of
hyperkalemia on the heart;
should be monitored closely
by ECG when given; onset ~1
to 2 minutes; duration is
~10 to 30 minutes.
Pediatric: 60–200 mg/kg over 3 to
5 minutes slow IV push.
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Table 3 Pharmacologic therapies for the treatment of tumor lysis syndrome (TLS) [3] (Continued)
Loop diuretics Inhibits reabsorption of Na+
and chloride, thus causing
increased excretion of fluid,
K+, and phosphate.
Adult: bumetanide: 0.5-1 mg IV
or PO 1 to 2 times per day (1 mg =
40 mg furosemide); ethacrynic
acid (PO) or ethacrynate
sodium (IV [Edecrin, Merck]): 0.5-
1 mg/kg/dose IV or PO q8-12h
prn; furosemide: 20–80 mg/dose
IV or PO q6-12h prn; torsemide:
10–20 mg IV or PO every day prn
(20–30 mg = 40 mg furosemide).
Onset: IV ~5 minutes; PO
~30 to 60 minutes; duration
~6 to 12 hours, depending on




(>6 months): 0.015-0.1 mg/kg/dose
once or twice daily (safety and
efficacy have not been
established in children <18);
ethacrynic acid: 25 mg PO daily
(maximum dose, 2–3 mg/kg/d);
furosemide 1–2 mg/kg/dose IV




Shifts K+ intracellularly. Adult: D5W at 0.5-1 mL/kg and
regular insulin 1 unit for every
4–5 g of dextrose given.
Onset is usually within 30 to
60 minutes; effects are
temporary, usually lasting 2
to 6 hours.
Pediatric: The dosage of regular
insulin is 1 unit for every 4–5 g
of dextrose; usually dextrose 25%
or 50% (0.5-1 g/kg) is used with
insulin; dextrose 0.5-1 g/kg can
also be infused over 15 to




Increases serum pH and causes
a temporary shift of K+ into cells.
Adult: 50 mEq as IV bolus, or 50–
150 mEq added to 1 liter D5W
and administered as an infusion.
Indicated for patients with
acidosis; onset ~30 to
60 minutes and may last 2 to
6 hours, but effects are
temporary (Sodium acetate




bicarbonate is determined to be
necessary, an initial dose of
1 mEq/kg may be given initially
either IV or per intraosseous
route, followed by not more than
half of that dose every
10 minutes as needed.
Hyperphosphatemia Calcium acetate
(PhosLo, Nabi)
Binds to phosphate taken in
through diet to form insoluble
calcium phosphate, which is
then excreted from the body
without being absorbed.
Adult: 2 tablets or gelcaps
(667 mg) with each meal; dosage
may be increased gradually to bring
serum phosphate value
<6 mg/dL as long as hypercalcemia
does not develop.
Adverse events include nausea,
mild hypercalcemia
(manifested as constipation,
anorexia, nausea and vomiting),
severe hypercalcemia
(associated with confusion,
delirium, stupor, coma), and
pruritus. Not recommended
unless patient is symptomatic
because of potential for







hydrochloride) is a cationic
polymer that binds intestinal
phosphate. The compound
contains multiple amines that
are protonated in the intestinal
tract and interact with phosphate
via ion-exchange and hydrogen
bonding.
Adult (PO): Recommended





dyspnea. Sevelamer is a
calcium- and aluminum-free




Pediatric (PO): Clinical data are
lacking.
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0.05 mg/kg [44-51]. A retrospective review from 2006
examined the efficacy of a fixed 3 mg dose of rasburicase
given to 43 patients with hematologic malignancies who
were receiving chemotherapy or hematopoietic stem cell
transplantation. All subjects in the study were hyperuri-
cemic, with 15 patients having laboratory values suggest-
ive of TLS and the remainder at elevated risk for TLS.
Patients were given allopurinol “as required”, to suppress
UA formation. Most patients experienced a significant
decline in UA within the first 24 hours, and 6 subjects
required an additional dose of rasburicase: 2 received a
1.5 mg second dose and 4 received a 3 mg second dose.
Within 48 hours, UA had normalized in all patients and
none required a third dose [51].
A retrospective review from 2009 assessed the use of a
weight-based approach to rasburicase therapy in 21 can-
cer patients, with dosing based on ideal body weight
(n=11); in cases where a patient was in excess of 30% of
the IBW (n=10), an adjusted dose was given. The aver-
age initial dose administered was 0.15 mg/kg ± 0.03. All
patients in the study had laboratory values reflecting
TLS or high risk for TLS, and all patients received allo-
purinol. Within 6 hours of treatment, the mean reduc-
tion from baseline of UA was 65.3% ± 17.3, and within
24 hours UA levels had been reduced by 89.7% ± 9.0%.
No data regarding additional doses was reported [47].
Fixed-dose efficacy has also been shown in a small num-
ber of patients with spontaneous TLS [45].
A recently published chart review from our institution
of single fixed-dose and weight-based dosing of rasburi-
case in 373 evaluated patients with malignancies, but at
varying levels of risk for TLS, sought to determine the
efficacy of these approaches to dosing in a larger and
more diverse patient population [52]. The primary end-
point of this chart review was normalization of UA at 24
hours; secondary endpoints were UA normalization at 48
and 72 hours [52]. Treatment across all groups was found
to be highly effective, with only 6 study subjects failing to
achieve normalized UA levels within 24 hours. There
were no significant differences between dosing groups for
any of the endpoints, although 3 mg was found to have a
weaker effect on UA reduction. That is, while the 3 mg
dose was equally effective at achieving treatment success
(i.e., <7.5 mg/dL within 24 hours), the mean UA level at
24 hours in the 3 mg group was 3.69 mg/dL compared to
1.71 mg/dL , 1.42 mg/dL , and 1.03 mg/dL in the 6 mg,
7.5 mg, and weight-based dosing groups, respectively
[52]. No significant differences between low, intermediate,
and high-risk patient groups were observed at 24 or 72
hours, while such a difference was observed at 48 hours
in the low-risk group (P=0.017) [52].
A recent randomized, open-label clinical trial compared
two rasburicase regimens in 80 patients at high risk for
TLS (defined as presence of hyperuricemia or very ag-
gressive lymphoma or leukemia) or potential risk (defined
as aggressive lymphoma or leukemia plus LDH ≥upper
normal limit, or stage or stage ≥3 disease, or stage 1 or 2
disease with ≥1 lymph node/tumor >5 cm) [53]. The regi-
mens were 0.15 mg/kg given as a single dose followed by
as-needed dosing versus the same dose given daily for 5
days. All but 1 patient experienced normalized UA within
24 hours, and UA reached undetectable levels within 4
hours for 84% of the study subjects. UA levels were
largely sustained in both groups with the notable
exception of 5 patients in the high-risk, single-dose arm
who required a second dose during the 5-day study
period. Two of these patients required a second dose on
day 3, 1 patient on day 4, and 1 patient on day 5. All 5 of
these patients had very aggressive lymphoma and/or
bulky tumor, including 3 with diffuse large B-cell lymph-
oma, 1 with Burkitt lymphoma, and 1 with Burkitt-like
disease. No patients required a third dose [53].
Experience with rasburicase has shown it to be largely
well tolerated, with side effects of this agent tending to
cluster around hypersensitivity/allergic reactions. These
include rash/pruritus, methemoglobinemia, fever, neu-
tropenia, hypoxia, and, rarely, anaphylactic shock.
Anemia can also occur, and, as previously noted, patients
with G6PD deficiency should not be treated with ras-
buricase [52-55]. In the one head-to-head open-label
study in which treatment with a single dose of rasburi-
case was compared to five daily doses, the incidence of
the most common side effects—generally mild to moder-
ate in severity (eg, nausea, constipation, diarrhea, and
vomiting)—was notably less in the single-dose treatment
group [53].





Adult: 500–2,000 mg elemental
calcium PO in divided doses; 2–
3 g Ca++ gluconate IV over 1
to 2 hours.
Reserved for patients who are
symptomatic; elemental
Ca++ content: carbonate
(40%) > chloride (27%) > acetate
(25%) > gluconate (9%);
IV Ca++ gluconate is less
irritating than other Ca++ salts.
Pediatric: 200–2,000 mg
elemental calcium PO in divided
doses; Ca++ gluconate 100 mg/kg
dose IV over 1 to 2 hours.
ECG, electrocardiogram; IV, intravenous; PO, by mouth, mEq; milliequivalent.
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Conclusions
The development of a wider range of cytotoxic therapies
and the application of, in some cases, more intensive
therapy for the treatment of a variety of cancer types has
increased the risk of TLS and the spectrum of its mani-
festations. Whereas TLS has been widely regarded as
associated with hematologic malignancies, an increasing
number of reports show that TLS also occurs in solid
tumors. In addition, spontaneous TLS is seen more fre-
quently, albeit it represents a minority of TLS cases.
The impact of TLS, as an oncologic emergency, often
extends beyond the immediate consequences of the condi-
tion itself. In many cases TLS can cause delay of necessary
chemotherapy, force a reduction in chemotherapy dosing
and alter the selection of cytotoxic agents due to treatment
toxicities overlapping with damage induced by TLS. Kidney
damage, heart failure, fluid retention, neuromuscular
effects, as well as gastrointestinal effects, are examples of
damage that can occur. As many practitioners in the clin-
ical setting have yet to fully realize the consequences of
TLS, often associated with more effective cancer treat-
ments and newer regimens, the likelihood of cancer
patients at risk for TLS is probably underestimated, result-
ing in unnecessary patient morbidity and mortality [54,55].
With the availability of highly effective treatments for
the prevention and management of TLS, it is worth reiter-
ating the importance of risk assessment in cancer patients.
Clinical experience has definitively demonstrated that the
provision of appropriate prophylactic therapy for TLS at
the appropriate dose can be the difference between suc-
cessful and unsuccessful outcomes in at-risk patients. Pre-
ventive and therapeutic interventions for TLS have been
shown to be highly effective and relatively easy to imple-
ment. (See Table 3 for a synopsis of pharmacologic therap-
ies for the treatment of TLS).
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